General MedicationsORALGeneric

PREVACID NAPRAPAC 500 (COPACKAGED)

LANSOPRAZOLE; NAPROXEN

Standard Dose

15MG,N/A;N/A,500MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview PREVACID NAPRAPAC 500 (COPACKAGED) is listed in Drugs@FDA under application 021507 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LANSOPRAZOLE; NAPROXEN Form and strength CAPSULE, DELAYED REL PELLETS, TABLET;ORAL - 15MG,N/A;N/A,500MG Sponsor TAKEDA PHARMS NA Submission history Latest submission status date: 2009-07-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview PREVACID NAPRAPAC 500 (COPACKAGED) is listed in Drugs@FDA under application 021507 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LANSOPRAZOLE; NAPROXEN Form and strength CAPSULE, DELAYED REL PELLETS, TABLET;ORAL - 15MG,N/A;N/A,500MG Sponsor TAKEDA PHARMS NA Submission history Latest submission status date: 2009-07-31 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.